ATAI Life Sciences N.V. (ATAI)

NASDAQ: ATAI · IEX Real-Time Price · USD
3.22
-0.11 (-3.30%)
Sep 23, 2022 4:00 PM EDT - Market closed
-3.30%
Market Cap 534.12M
Revenue (ttm) 20.38M
Net Income (ttm) -193.52M
Shares Out 165.88M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 795,007
Open 3.34
Previous Close 3.33
Day's Range 3.15 - 3.38
52-Week Range 2.95 - 17.81
Beta n/a
Analysts Buy
Price Target 24.44 (+659.0%)
Earnings Date Aug 15, 2022

About ATAI

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of i... [Read more...]

Industry Biotechnology
IPO Date Jun 18, 2021
Employees 87
Stock Exchange NASDAQ
Ticker Symbol ATAI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for ATAI stock is "Buy." The 12-month stock price forecast is 24.44, which is an increase of 659.01% from the latest price.

Price Target
$24.44
(659.01% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant

They haven't experienced any setbacks, but their shares are still down.

Other symbols: CMPS
2 weeks ago - The Motley Fool

atai Life Sciences to Participate in September Investor Events

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health dis...

2 weeks ago - GlobeNewsWire

2 Top Trends to Invest $2,000 in Ahead of the Crowd

These two trends on the frontier of medicine could present lucrative opportunities for investment.

Other symbols: CMPS
2 weeks ago - The Motley Fool

7 Psychedelics Stocks to Buy for a Big Drug Boom

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and s...

3 weeks ago - InvestorPlace

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai's development prog...

1 month ago - GlobeNewsWire

atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital

-  Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments

1 month ago - GlobeNewsWire

atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update

NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health diso...

1 month ago - GlobeNewsWire

New Regulations for Psychedelics? Here's What Investors Need to Know

There are a couple of proposed regulations and policies in the pipeline.

Other symbols: COMP
2 months ago - The Motley Fool

Dear Psychedelic Stocks Fans, Watch This Key Catalyst

Psychedelic stocks are in focus following new legislation from both the Senate and the House that has bipartisan support. The post Dear Psychedelic Stocks Fans, Watch This Key Catalyst appeared first on...

Other symbols: CMPSMNMD
2 months ago - InvestorPlace

5 New Cathie Wood Stocks to Watch Right Now

Cathie Wood remains bullish on staple ARK names like Tesla and Teladoc. Still, the fund manager has added several new companies to her ETFs.

Other symbols: BFLYDDDSTNESURF
2 months ago - InvestorPlace

atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer

Dr. Chad Beyer will join as CEO on July 1, 2022 Dr. Chad Beyer will join as CEO on July 1, 2022

2 months ago - GlobeNewsWire

Stephen Bardin to Join atai Life Sciences as CFO Designate

NEW YORK and BERLIN, June 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (Nasdaq: ATAI) (“atai” or the “Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of ...

3 months ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming June Healthcare Conferences

NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health diso...

3 months ago - GlobeNewsWire

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

– Strong execution across atai's three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health

4 months ago - GlobeNewsWire

CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued yesterday under the headline "atai Life Sciences to Announce First-Quarter 2022 Financial Results" by atai Life Sciences N.V. (Nasdaq: ATAI...

4 months ago - GlobeNewsWire

atai Life Sciences to Announce First-Quarter 2022 Financial Results

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will ...

4 months ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming April Investor Conference

NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, wil...

5 months ago - GlobeNewsWire

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlig...

–   Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitiv...

5 months ago - GlobeNewsWire

atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 a...

NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health dis...

6 months ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming March Investor Conferences

NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, wil...

6 months ago - GlobeNewsWire

atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in...

- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions

7 months ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming February Investor Conference

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will...

7 months ago - GlobeNewsWire

ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments

atai Life Sciences on Thursday announced Invyxis, a new program to accelerate the company's portfolio of compounds.

7 months ago - Benzinga

atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai's portfolio of new chemical entities (NCEs)

7 months ago - GlobeNewsWire